Abstract 113P
Background
Capecitabine-induced hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia is a common adverse event that has a major negative impact on patients' quality of life. The associating or predictive factors of capecitabine-induced HFS are still unclear. This study aimed to evaluate the associating factors in the development of HFS in colorectal cancer patients who received capecitabine and to analyze the association between HFS and survival in patients with stage IV disease.
Methods
This study was a single-institution retrospective study. The medical records of 214 patients with stage II-IV colorectal cancer who received capecitabine between January 2019 and November 2023 were reviewed. Associating factors of capecitabine-induced HFS, which were categorized into grade 0-1 and grade 2-3 were analyzed using univariate and multivariate logistic regression analyses. Kaplan-Meier methods were used to analyze the progression-free survival (PFS) and overall survival (OS) of patients with stage IV colorectal cancer.
Results
157 of 214 (73%) patients developed HFS, of which grade 2-3 HFS were 29.3%. The multivariate logistic regression analysis revealed age ≥60 years (odds ratio [OR], 3.8; 95% confidence interval [CI], 1.35 to 10.66; P=0.011) and capecitabine monotherapy (OR, 4.46; 95% CI, 1.94 to 10.23; P<0.001) were significantly associating factors in the development of grade 2-3 HFS. There was no difference in terms of PFS and OS in patients with stage IV colorectal cancer who developed either grade 2-3 HFS or grade 0-1 HFS.
Conclusions
One-third of patients with colorectal cancer who received capecitabine developed grade 2-3 HFS, with age ≥60 years and capecitabine monotherapy being important associating factors. There was no correlation between the severity of HFS and survival in patients with stage IV colorectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institutional Review Board of Royal Thai Army Medical Department.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.